Nathanael L. Dirks, Pharm.D., Ph.D.

Principal Scientist II

Nathanael joined Metrum in 2010 after receiving his Pharm.D. and Ph.D. (Pharmaceutical Sciences). In his tenure at Metrum, Nathanael has applied both clinical pharmacy knowledge and pharmacometric methods to PK/PD modeling and simulation analyses and strategic decision making at all stages of drug development. His clinical experience spans a broad range of small molecule and biologic therapeutics in a number of therapeutic areas with particular emphasis in pediatric pharmacology, rare diseases, pain management, and inflammatory diseases.

Recent publications by this scientist

Exposure–efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn’s disease and ulcerative colitis

March 6, 2024

This posthoc analysis of the GEMINI and VISIBLE studies in ulcerative colitis (UC) and Crohn’s Disease (CD) assessed exposure−efficacy of vedolizumab intravenous (IV) and subcutaneous (SC).

Read Article

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease.

January 13, 2021

Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Intest Res. 2021;19(1):95-105. doi:10.5217/ir.2019.09167.

View More

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

January 29, 2019

Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR. Aliment Pharmacol Ther. 49(4):408–18. February 2019.

View More